Nicolas Girard, AACR 2022: CheckMate-816 Investigating Neoadjuvant Nivolumab Plus Chemotherapy for Non-small Cell Lung Cancer
It was a pleasure to talk with Prof. Nicolas Girard (Institut Curie; Versailles Saint Quentin University, Paris, France) to discuss the findings from his analysis of event-free survival in the CheckMate-816 trial, investigating neoadjuvant nivolumab plus chemotherapy for resectable (IB-IIIA) non-small cell lung cancer. The abstract ‘Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!